Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study To Evaluate The Pharmacokinetics And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Children And Adolescents 7-17 Years Of Age Who Require Opioid Analgesia

NCT02680847 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02680847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02680847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study To Evaluate The Pharmacokinetics And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Children And Adolescents 7-17 Years Of Age Who Require Opioid Analgesia
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Terminated
Start date
January 21, 2016
Completion date
January 24, 2018
Enrollment
32 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-severe pain